POS0626 MONEY MATTERS: ASSESSING THE VALUE OF THE ADALIMUMAB BIOSIMILAR SWITCH FOR RHEUMATOLOGY PATIENTS

Background: The adalimumab biosimilar switch plan, actioned 2018-19 was one of the most complex all biologic switches across several specialties. Non-medical are considered to ensure best value medicines prescribed for patients in line with NICE Technology Appraisals. Objectives: This 2 year follow up review explores Rheumatology (R) comparison two other major specialisms; Dermatology and Gastroenterology (G). Methods: 403 homecare (HC) had been identified as eligible a citrate containing (R;189, G;176, D;38) between April-December 2019. 35 hospital FP10 receiving citrate-free originator were also prescription processing via HC (R; 24, G; 9, D;2). Biosimilar information communicated patient letters/clinic reviews. received remote pharmacist telephone support, part PDSA (Plan, Do, Study, Act) quality improvement pilot. Data regard refusal, treatment cessation, withheld satisfaction ratings phonecalls (1 = unsatisfactory, 5=very satisfied) documented. Results: 235/403 successfully switched (R;99, G;107, D;29). 64/403 back (R;47, G;12; D;5). Of 64 patients; 52% reported lack efficacy; 27% injection site pain 21% various factors such blepharitis, insomnia hair loss. 38/403 refused remained on (R;11, G;27, D;0). 31/403 an alternative (R;19, G;9, D;3). 32/403 stopped (R;13, G;19, Treatment 3/403 (R;0, G;2, D;1). 100% HC. 31/35 22, 7, D; 2). 3/31 due efficacy or side effects. 4 (R;3, G;1, 89% very satisfied support. Conclusion: In summary, 58% who support; total cost saving following £270,000. demonstrated least success switching (52%) highest figure (25%). Injection subjective appear be main reasons ongoing backs. project demonstrates that thorough assessment concerns rationalising use agent versus can valuable patients. Further effective biosimilars have recently launched. seminal emphasises need robust critical appraisals biosimilars, consideration both clinical parameters, before establishing their placement pathways. Acknowledgements: Mark Easter, UHCW Interim Integrated Care System Chief Pharmacist, Hardeep Bagga, Deputy Pharmacy Homecare Team Specialist Rheumatology, Clinical Teams. Disclosure Interests: None declared